Efficacy and safety of long-term thiopurine maintenance treatment for ulcerative colitis in Turkey: A single-center experience

Basit Öğe Kaydı
dc.contributor.authorOzgenc, Funda
dc.contributor.authorKarakoyun, Miray
dc.contributor.authorEcevit, Cigdem
dc.contributor.authorHekimci, Hamiyet
dc.contributor.authorTasci, Ezgi Kiran
dc.contributor.authorErdemir, Gulin
dc.date.accessioned2019-10-27T10:01:09Z
dc.date.available2019-10-27T10:01:09Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/Aims: Thiopurines are widely used in the treatment of inflammatory bowel disease, but data are limited. Or aim was to determine the outcome of thiopurine application in children diagnosed with ulcerative colitis (UC). Materials and Methods: Forty-eight patients with UC, diagnosed at our center between 2005 and 2016 and applied azathiopurine (AZA), were included in the study. Data were collected retrospectively. The diagnosis of UC was based on the conventional clinical, radiological, histological, and endoscopic assessment. All patients with UC at this intercept were analyzed at the 4- and 6-week and 3-month intervals after remission to determine patient characteristics, thiopurine properties, and its efficacy and toxicity. Determination of remission, relapse, and steroid refractoriness/dependency were guided according to the European Crohn's and Colitis Organisation consensus. Results: Azathiopurine was started at the median 1 month (0-12 months), and it was applied thereafter for maintenance (n=43). Response to remission induction was obtained in 40 (93.7%) patients. The median duration of the AZA treatment was 24 months (5-63). In 34 (85%) of the 40 children, it was well tolerated until the last visit. During the follow-up, adverse events occurred in 6 patients. These are leucopenia, neutropenia, vomiting, diarrhea, and skin rush. Conclusion: Thiopurine is an appropriate treatment option for remission in patients with UC. For a long-term follow-up, it is very important to identify patients with UC who have clinical remission with side effects and with thiopurine application.en_US
dc.identifier.doi10.5152/tjg.2018.17151
dc.identifier.endpage654en_US
dc.identifier.issn1300-4948
dc.identifier.issn2148-5607
dc.identifier.issue6en_US
dc.identifier.pmid30381272en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage650en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2018.17151
dc.identifier.urihttps://hdl.handle.net/11454/29812
dc.identifier.volume29en_US
dc.identifier.wosWOS:000449010500005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectUlcerative colitisen_US
dc.subjectazathiopurineen_US
dc.subjecteffectivenessen_US
dc.subjectadverse eventsen_US
dc.titleEfficacy and safety of long-term thiopurine maintenance treatment for ulcerative colitis in Turkey: A single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu